{"nctId":"NCT02562755","briefTitle":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone","startDateStruct":{"date":"2015-10","type":"ACTUAL"},"conditions":["Hepatocellular Carcinoma (HCC)"],"count":459,"armGroups":[{"label":"Pexa-Vec followed by Sorafenib","type":"EXPERIMENTAL","interventionNames":["Biological: Pexastimogene Devacirepvec (Pexa Vec)","Drug: Sorafenib"]},{"label":"Sorafenib","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sorafenib"]}],"interventions":[{"name":"Pexastimogene Devacirepvec (Pexa Vec)","otherNames":["JX-594"]},{"name":"Sorafenib","otherNames":["Nexavar"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological/cytological diagnosis of primary HCC\n* Advanced stage HCC (Barcelona Clinic Liver Cancer \\[BCLC\\] Stage C or B per American Association for the Study of Liver Disease \\[AASLD\\] guidelines)\n* At least one measurable viable tumor in the liver, â‰¥1 cm longest diameter (LD), using a dynamic imaging technique (arterial phase of triphasic computerized tomography \\[CT\\] scan, or dynamic contrast-enhanced magnetic resonance imaging \\[MRI\\]), and injectable under imaging-guidance (CT and/or ultrasound)\n* Child-Pugh Class A\n* Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Adequate hematological, hepatic, and renal function:\n* Additional inclusion criteria exist\n\nExclusion Criteria:\n\n* Histological diagnosis of cholangiocarcinoma, hepatocholangiocarcinoma, fibrolamellar carcinoma and hepatoblastoma\n* Symptomatic cardiovascular disease, including but not limited to significant coronary artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months\n* Current or past history of cardiovascular disease (e.g.. past history of myocardial infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has been obtained for study participation\n* History of moderate or severe ascites, bleeding esophageal varices, hepatic encephalopathy or pleural effusions related to liver insufficiency within 6 months of screening\n* Bulky disease patients - tumors encompassing \\>50% of the liver volume and / or inferior vena cava invasion\n* Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or immune-suppressive medication including high-dose corticosteroids\n* Ongoing severe inflammatory skin condition (as determined by the Investigator) requiring medical treatment\n* History of severe eczema (as determined by the Investigator) requiring medical treatment\n* Additional exclusion criteria exist","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR)","description":"Percentage of participants who showed overall response during their participation in the study. Per Modified Response Evaluation Criteria In Solid Tumors Criteria (mRECIST) and assessed by tri-phasic contrast enhanced CT: Complete Response (CR), Disappearance of intratumoral enhancing area; Partial Response (PR), \\>=30% decrease in the sum of the diameters of enhancing area; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":null},{"groupId":"OG001","value":"20.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":117,"n":218},"commonTop":["Diarrhoea","Pyrexia","Palmar plantar erythrodysaesthesia syndrome","Decreased appetite","Nausea"]}}}